Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

INSIDE INFORMATION
FORECAST OF 2026 INTERIM REVENUE

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") in accordance with Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board ("**Board**") of directors ("**Directors**") of the Company is pleased to announce that based on the preliminary review on the Group's latest unaudited consolidated management accounts for the six months ended June 30, 2026 (the "**Reporting Period**") and currently available information, the Group expects to achieve revenue of approximately RMB63 million to RMB65 million, representing an increase of approximately RMB50 million to RMB52 million compared with the same period last year, with a year-on-year increase of approximately 385% to 400%. Other income and gains is expected to achieve approximately RMB9 million to RMB11 million, amounting to a total of approximately RMB72 million to RMB76 million, representing an increase of approximately RMB47 million to RMB51 million compared with the same period last year, with a year-on-year increase of approximately 188% to 204%.

The main reasons for the performance growth during the Reporting Period include:

1. Ken-Valve, the Group's transcatheter aortic valve replacement system delivered solid growth in revenue from commercialization. Indicated for aortic regurgitation or combined with aortic stenosis, the advantages of Ken-Valve's design features and clinical performance have enabled the rapid adoption and penetration of the therapy across multi-tier medical institutions;

2. The Group's multiple structural heart interventional products have been actively applied in reimbursed clinical implantations overseas. The favorable clinical outcomes and application advantages of the Group's product portfolio have earned high recognition from key opinion leaders and experts worldwide, addressing the vast long-unmet clinical needs in structural heart diseases globally.

The Group will continue to advance the development of multiple innovative product portfolio and further deepen our global business layout to achieve sustainable revenue growth; and will further enhance management efficiency and reduce operating costs in production, supply chain, and operational management to achieve long-term strategic development goals.

As of the date of this announcement, the Company is still in the process of preparing and finalizing the interim results of the Group for the Reporting Period. The above operating information is preliminary unaudited information and has not been reviewed, confirmed or audited by the auditors of the Company, or reviewed by the audit committee of the Board. It is for investors' reference only and shall not be considered as a measure or indicator of the future financial performance of the Group. Shareholders and potential investors are advised to read thoroughly the results announcement of the Company in respect of the Group for the Reporting Period, which is expected to be released in August 2026 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, August 10, 2026

As at the date of this announcement, the executive Director of the Company is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.